Allogene Therapeutics
Joy C. currently serves as Associate Director of Translational Sciences at Allogene Therapeutics, a position held since February 2021, after progressing from Senior Manager in the same field. Prior to this role, Joy C. was a stay-at-home mom and held various positions at Coherus BioSciences from May 2016 to January 2020, including Senior Project Manager and Project Manager in Translational Sciences. Experience also includes a Project Coordinator role at Genentech and significant research contributions at Cellerant Therapeutics, including the development of Megakaryocyte Progenitor Cells that earned a patent. Educational credentials include a Master's in Biosciences from San Francisco State University and a Certificate in Clinical Research Conduct and Management from the University of California, Berkeley.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.